~(18)F-FDG PET/CT诊断肾脏病合并肿瘤

详细信息    查看全文 | 推荐本文 |

英文篇名：~(18)F-FDG PET/CT in diagnosis of renal disease combined with tumor 作者：康磊 ; 范岩 ; 刘莉 ; 张建华 ; 杜毓菁 ; 张炳晔 ; 王荣福 英文作者：KANG Lei;FAN Yan;LIU Li;ZHANG Jianhua;DU Yujing;ZHANG Bingye;WANG Rongfu;Department of Nuclear Medicine,Peking University First Hospital;Department of Nephrology,Peking University First Hospital; 关键词：肾脏病 ; 肿瘤 ; 正电子发射体层摄影术 ; 氟脱氧葡萄糖F18 英文关键词：renal disease;;neoplasms;;positron-emission tomography;;fluorodeoxyglucose F 18 中文刊名：ZYXX 英文刊名：Chinese Journal of Medical Imaging Technology 机构：北京大学第一医院核医学科;北京大学第一医院肾内科; 出版日期：2019-03-20 出版单位：中国医学影像技术 年：2019 期：v.35;No.310 基金：国家自然科学基金面上项目(81871385);; 十二五国家支撑项目基金(2014BAA03B03);; 北京市科技新星人才计划(Z171100001117024);; 北京市科技新星计划交叉学科合作课题(Z181100006218126);; 北京大学医学部医学交叉种子基金(BMU2017MX005) 语种：中文; 页：ZYXX201903031 页数：4 CN：03 ISSN：11-1881/R 分类号：89-92

摘要

目的评价~(18)F-FDG PET/CT诊断肾脏病合并肿瘤的应用价值。方法回顾性分析146例肾脏病患者的~(18)F-FDG PET/CT表现,检测病灶最大标准摄取值(SUV_(max));以病理学结果作为诊断金标准,计算~(18)F-FDG PET/CT对肾脏病合并肿瘤的诊断效能。结果 146例肾脏病患者中,29例并发恶性肿瘤,其中肿瘤继发肾损害19例、肾损害伴发肿瘤10例。PET/CT发现72例存在~(18)F-FDG高摄取灶,病灶SUV_(max)为5.25±3.94;诊断肿瘤34例,最终确诊29例、误诊5例,诊断灵敏度100%(29/29),特异度88.37%(38/43)。肿瘤继发肾损害病灶SUV_(max)为5.95±3.02,肾损害伴发肿瘤病灶SUV_(max)为6.58±5.29,差异无统计学意义(P>0.05)。结论 ~(18)F-FDG PET/CT可用于筛查肾脏病患者是否合并肿瘤,但对于肿瘤与肾损害关系的诊断价值有限。
        Objective To explore the value of ~(18)F-FDG PET/CT in diagnosing renal disease combined with tumor.Methods ~(18)F-FDG PET/CT data of 146 patients with renal disease were retrospectively analyzed.The maximum standardized uptake value(SUV_(max))was measured.The results of pathology were taken as the final diagnostic criteria to evaluate the efficacy of ~(18)F-FDG PET/CT in diagnosing tumor in patients with renal disease.Results Totally 29 cases were found combined with tumor,including 19 cases with renal damage secondary to tumors and 10 cases as nephropathy coincident with tumors.PET/CT found 72 cases of ~(18)F-FDG uptake increased(SUV_(max)=5.25±3.94).~(18)F-FDG PET/CT diagnosed tumors in 34 cases,including 29 cases were then confirmed and 5 misdiagnosed,the diagnostic sensitivity and specificity of PET/CT was 100%(29/29)and 88.37%(38/43),respectively.SUV_(max) of lesions of secondary nephropathy by tumor was 5.95±3.02,SUV_(max) of lesions of nephropathy coincident with tumor was 6.58±5.29,there was no significant difference(P>0.05).Conclusion ~(18)F-FDG PET/CT may be used to screen tumors in patients with renal disease,but it has limited value to explore the relationship between renal disease and tumor.

引文

[1] Lien YH, Lai LW. Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis. Nat Rev Nephrol, 2011,7(2):85-95.
    [2] Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: Clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol, 2010,30(6):570-581.
    [3] Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: The renal insufficiency and anticancer medications (IRMA) study. Cancer, 2007,110(6):1376-1384.
    [4] 康磊,徐小洁,范岩,等.18F-FDG PET/CT在不明原因发热中的诊断价值.北京大学学报(医学版), 2015,47(1):175-180.
    [5] 张建华,王荣福,范岩,等.18F-FDG PET/CT在肾脏肿瘤诊疗中的应用.中国医学影像技术,2012,28(3):548-553.
    [6] Tu H, Wen CP, Tsai SP, et al. Cancer risk associated with chronic diseases and disease markers: Prospective cohort study. BMJ, 2018,360:k134.
    [7] Jorgensen L, Heuch I, Jenssen T, et al. Association of albuminuria and cancer incidence. J Am Soc Nephrol, 2008,19(5):992-998.
    [8] Kode V, Karsch H, Osman MM, et al. Impact of renal failure on 18F-FDG PET/CT scans. Front Oncol, 2017,7:155.
    [9] Pani A, Porta C, Cosmai L, et al. Glomerular diseases and cancer: Evaluation of underlying malignancy. J Nephrol, 2016,29(2):143-152.
    [10] Chien CC, Han MM, Chiu YH, et al. Epidemiology of cancer in end-stage renal disease dialysis patients: A national cohort study in Taiwan. J Cancer, 2017,8(1):9-18.
    [11] 刘红洁,王荣福,张春丽,等.肾脏不同类型恶性病变18F-FDG标准摄取最大值的比较.中国医学影像技术,2015,31(6):913-916.
    [12] Salahudeen AK, Bonventre JV. Onconephrology: The latest frontier in the war against kidney disease. J Am Soc Nephrol, 2013,24(1):26-30.
    [13] Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: A consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol, 2010,28(33):4976-4984.
    [14] 刘萌,廖栩鹤,王荣福,等.18F-FDG PET/CT在弥漫大B细胞淋巴瘤免疫亚型诊断中的应用.中国医学影像技术,2016,32(1):75-78.